# Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously

> **NCT00635414** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 60 (estimated)

## Conditions studied

- GERD

## Interventions

- **DRUG:** Esomeprazole
- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT00635414
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2002-10
- **Final completion:** 2002-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2011-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635414, "Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00635414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*